Levi & Korsinsky has commenced an investigation into Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) concerning possible violations of federal securities laws.

Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws.

On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease. While the trial met one of its primary endpoints, it failed to achieve in the other, falling shy of a statistically significant improvement in annualized rate of pain ("pain crises"). Additionally, the "key secondary endpoint of change from baseline in PROMIS Fatigue was not met." Following this news, Agios' stock price fell by $22.33 per share to open at $23.16 per share.

http://www.datamonitor.com
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon
COMTEX_478962620/2227/2026-05-11T22:36:33